Result of WRAP Retail Offer

Medpal AI PLC

25 March 2026

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF THE LAWS OF ENGLAND AND WALES PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.

25 March 2026

MedPal AI Plc

("MedPal AI" or the "Company")

Result of WRAP Retail Offer

Further to its announcement of 20 March 2026, MedPal AI plc (AIM: MPAL, FRA:Z1N), the UK digital health and AI company, is pleased to confirm the result of its WRAP Retail Offer ("WRAP"). The WRAP Retail Offer has raised gross proceeds of approximately £105,160. In addition the Company has entered into a subscription agreement to raise a further £300,000 at 2.5p per share (the "Subscription"). With the proceeds of the Placing of £527,000 announced on 20 March 2026, in aggregate the Company has therefore raised gross proceeds of approximately £932,160 at a price of 2.5 pence per new ordinary share. The Company will issue 16,206,396 new Ordinary Shares ("Fundraise Shares") in respect of the WRAP and the Subscription.

Admission and Total Voting Rights

Application has been made for the Fundraise Shares to be admitted to trading on AIM along with the Placing Shares ("Admission"). Admission is expected to become effective and dealings in the shares are expected to commence on or around 26 March 2026.

Upon Admission, the Company's issued ordinary share capital will consist of 492,441,036 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission the total number of Ordinary Shares and voting rights in the Company will be 492,441,036. With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The new Ordinary Shares to be issued pursuant to the Placing, Subscription and WRAP Retail Offer will be issued free of all liens, charges and encumbrances and will, on Admission, rank pari passu in all respects with the Company's existing Ordinary Shares.

Capitalised terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released on 20 March 2026.

For further information, please contact:

MedPal AI plc Jason Drummond	www.medpalplc.com
Cairn Financial Advisers LLP Louise O'Driscoll/Jo Turner	[phone]
Clear Capital Markets Limited Bob Roberts	[phone]
Winterflood Retail Access Platform Sophia Bechev, Kaitlan Billings	[e-mail] [phone]

Further information on the Company can be found on its website at www.medpalplc.com

 

END